Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
Michael R. McClung(Bone Health and Osteoporosis Foundation), Jose Adolfo Rodriguez-Portales(Pontificia Universidad Católica de Chile), Jeong‐Gun Park(Brigham and Women's Hospital), Henry G. Bone(University of Arizona), S. Aubrey Stoch(MACOM (United States)), Douglas P. Kiel(Harvard University), José Zanchetta(Universidad del Salvador), Norman Heyden(Merck & Co., Inc., Rahway, NJ, USA (United States)), Keith D. Kaufman(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marc S. Sabatine(Brigham and Women's Hospital), Rachid Massaad(MSD (Belgium)), Deborah M. Gurner(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kenneth G. Saag(University of Alabama at Birmingham), Arthur C. Santora(Merck & Co., Inc., Rahway, NJ, USA (United States)), Piet Geusens(KU Leuven), Kurt Lippuner(University of Bern), Ilaria Cavallari(Università Campus Bio-Medico), Socrates E. Papapoulos(Leiden University Medical Center), Ian R. Reid(University of Auckland), Deborah L. Miller(Cleveland Clinic), Abby Cange(Brigham and Women's Hospital), C. Roux(Hôpital Pasteur), Nadia Verbruggen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ling Xu(Capital Medical University), Ben Hur Albergaria, Michelle L. O’Donoghue(Brigham and Women's Hospital), Dosinda Cohn(Merck & Co., Inc., Rahway, NJ, USA (United States)), C. Magaril, Marc P. Bonaca(The Medical Center of Aurora), Z. Man(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stefan Goemaere(Ghent University Hospital), Cristiano A. F. Zerbini(Centro Paulista de Investigação Clinica), Toshitaka Nakamura(University of Occupational and Environmental Health Japan), KyungAh Im(Brigham and Women's Hospital), Boyd B. Scott, Micki L Blair(Merck & Co., Inc., Rahway, NJ, USA (United States)), Antonio Lombardi(TB Alliance), Laura T. Grip(Brigham and Women's Hospital), Stephen D. Wiviott(Brigham and Women's Hospital), Tobias De Villiers(Stellenbosch University), Adam B. Polis(Merck & Co., Inc., Rahway, NJ, USA (United States)), Albert Leung(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bente Langdahl(Aarhus University Hospital), Jean‐Yves Reginster(University of Liège), Philip N. Sambrook(The University of Sydney), C. Mautalén, Carolyn DaSilva(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 171
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k